Regeneron's COVID drug sales outside U.S. help revenue beat
Regeneron Pharmaceuticals reported better-than-expected revenue aided by sales from its COVID-19 antibody outside the United States and strong demand for its blockbuster drugs Dupixent and Eylea.
View the full story here: https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-quarterly-profit-drops-covid-antibody-sales-hit-2022-05-04/